

SECTOR: Specialty Pharmaceuticals

On 6/19/14, we attended a **Beef 101 Day** hosted by SmartVet (Private), which underscored our investment thesis that an increasing need for Animal Health drugs that support healthier and more productive livestock will drive earnings upside for companies such as ZTS and PAHC. Please see our note Deep Dive into Cattle Opportunity Suggests Growing Need for Drugs to Increase Productivity and Profitability. We spent an informative day in the heart of U.S. cattle country to get an overview of the **Beef Cattle Production Industry**, how it operates, animal health-care, parasite management and economic sustainability. We heard from leading industry experts, toured Kansas Cattle Ranch, and experienced live cattle parasite treatments (more details in body of the note). Key takeaways from our meeting which support our investment thesis are as follows:

- Cattle inventory is expected to grow through 2020. The drought caused 1.8MM cattle to be slaughtered. Producers are currently rebuilding their herd sizes, however breeding decisions taken today may take as long as 25 months to be seen in the cattle inventory.
- China could play a major role in driving demand for U.S. beef. If China lifts a ban on U.S. beef (from the 2003 BSE outbreak) this could significantly drive further demand and price increases for the U.S. cattle industry. Although no time-frame is currently in place for the lifting of the ban, last week Hong Kong lifted restrictions on U.S. beef imports. Japan is currently the U.S.'s largest export market with ~\$1.4B annually.
- Growing demand for beef will be driven by the East. The role of China will be very important going forward. The demand for beef products in China is expected to increase by 15% to 20% a year, for the next five years. U.S. beef is seen as premium beef in the Chinese market and as such is able to sustain higher prices than beef imported from other nations.
- One large, unmet need that Animal Health companies can help address are parasite resistance to existing drugs. Horn flies in particular have developed resistance. Many cattle are dosed at times which is not the most effective in managing parasites. However due to limitations, such as labor and weather, cattle are often dosed at times which are suitable for the producer, rather than optimal for pest management. Key opinion leaders estimate correct timing of dosing could lead to gains of one tenth to two tenths of a pound per day.

Potential Catalysts for Zoetis (ZTS, BUY, \$32.46): 1) Operating margin expansion; 2) new product launches; 3) business development; 4) expansion into adjacent categories; 5) new CFO.

LOUISE CHEN	ANALYST
louise.chen@guggenheimpartners.com	212 381 4195
SWATI KUMAR	ASSOCIATE
swati.kumar@guggenheimpartners.com	212 918 8754
BRANDON FOLKES	ASSOCIATE
brandon.folkes@guggenheimpartners.com	212 518 9976

Potential Catalysts for Phibro (PAHC, BUY, \$20.49): 1) F'15 guidance mid-September; 2) Increasing market share and geographic expansion of existing products, '14+; 3) New product approvals and launches, '14+; 4) Gross margin and operating margin expansion, 14+; 5) Debt paydown reduces interest expense, 14+; 6) Tuck-in acquisitions, '14+.

BEEF CATTLE PRODUCTION INDUSTRY

How Does it Operate

- The cattle industry is more segmented than the other livestock industries, such as pork or poultry, which are more integrated.
- The life cycle of beef cattle is normally 14 to 16 months, however this may vary depending on a variety of economic factors, such as feed prices, beef prices and demand.

Animal Healthcare

- When cattle consume food they can either use this food to grow mass or build up their immune system to fight parasites. The more effective the treatments given to cattle to fight parasites are, the more productive cattle are as they are able to build mass faster.
- Appetite suppression is one of the biggest side effects of internal parasites in cattle. Cattle which have appetite suppression from internal parasites will not produce mass as quickly.

Parasite Management and Live Cattle Experience

- Current treatments on the market are effective, however it is the timing, dosage and proper rotation between classes of pesticides, which is not performed correctly. Experts believe correct timing of dosing could add between one tenth and two tenths of a pound to cattle per day.
- The best times to treat cattle depend on the life stage the cattle are in. Calves are best treated in the middle of summer, however most producers do not do this due to the heat, availability of labor, as well as this often being the time when farmers are harvesting wheat.

Economic Sustainability

 The cattle industry is a cyclical industry and as such beef prices are cyclical too. The liquidation in herd sizes seen in the past few years has been driven by external forces. However, the cattle industry has shifted to more effective production methods, which has decreased the need for as many heads of cattle.

What We Learned on Our Tour of Kansas Cattle Ranch

- Cattle farming is a very intensive process and as such producers place a high value on technology which reduces the demand for time and labor.
- We witnessed a demonstration of SmartVet's Vetgun (for parasite management). Cattle were dosed in the field while grazing. Producers we spoke with were very positive and excited about the Vetgun and Vetcaps as the dosing took significantly less time, and cattle were able to continue grazing shortly after being dosed. The producer was also able to dose the cattle alone, without the need for additional labor. We were impressed with the effectiveness of the dosing as many of the horn flies seen on the cattle no longer existed shortly after dosing.

ANALYST CERTIFICATION

By issuing this research report, each Guggenheim Securities, LLC ("Guggenheim Securities") research analyst whose name appears in this report hereby certifies that (i) all of the views expressed in this report accurately reflect the research analyst's personal views about any and all of the subject securities or issuers discussed herein and (ii) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst.

IMPORTANT DISCLOSURES

The research analyst(s) and research associate(s) have received compensation based upon various factors, including quality of research, investor client feedback, and Guggenheim Securities, LLC's overall revenues, which includes investment banking revenues.


Guggenheim Securities, LLC managed or co-managed a public offering of securities for Phibro Animal Health Corporation during the past 12 months.

Phibro Animal Health Corporation and Zoetis Inc. are or were during the 12-month period preceding the date of the distribution of this report a client of Guggenheim Securities, LLC. Guggenheim Securities, LLC provided Phibro Animal Health Corporation and Zoetis Inc. investment banking services.

Guggenheim Securities, LLC or its affiliates received compensation for investment banking services from Phibro Animal Health Corporation and Zoetis Inc. during the past 12 months.

Guggenheim Securities, LLC or its affiliates expect(s) to receive or intend(s) to seek compensation for investment banking services from Phibro Animal Health Corporation and Zoetis Inc. in the next 3 months.

Please refer to this website for company-specific disclosures referenced in this report: <u>https://guggenheimsecurities.bluematrix.com/sellside/</u> <u>Disclosures.action</u>. Disclosure information is also available from Compliance, 330 Madison Avenue, New York, NY 10017.



SECTOR: SPECIALTY PHARMACEUTICALS



RATING DEFINITIONS

BUY (B) - Describes stocks that we expect to provide a total return (price appreciation plus yield) of 15% or more within a 12-month period.

NEUTRAL (N) - Describes stocks that we expect to provide a total return (price appreciation plus yield) of plus 15% or minus 15% within a 12-month period. **SELL (S)** - Describes stocks that we expect to provide a total negative return (price appreciation plus yield) of 15% or more within a 12-month period.

NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Guggenheim Securities, LLC policies.

CS - Coverage Suspended. Guggenheim Securities, LLC has suspended coverage of this company.

NC - Not covered. Guggenheim Securities, LLC does not cover this company.

Restricted - Describes issuers where, in conjunction with Guggenheim Securities, LLC engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.

Monitor - Describes stocks whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.

Guggenheim Securities, LLC methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/ FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.

RATINGS DISTRIBUTIONS FOR GUGGENHEIM SECURITIES:

Rating Category		Percent	IB Serv./ Past 12Mos.		
	Count		Count	Percent	
Buy	100	54.64%	22	22.00%	
Neutral	77	42.08%	3	3.90%	
Sell	6	3.28%	0	0.00%	

OTHER DISCLOSURES

This research is for our clients and prospective clients only. Other than disclosures relating to Guggenheim Securities and its affiliates, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis,

SECTOR: SPECIALTY PHARMACEUTICALS

the large majority of reports are published at irregular intervals as appropriate in the research analyst's judgment. Guggenheim Securities conducts a fullservice, integrated investment banking and brokerage business, and one or more of its affiliates conduct an investment management business. Guggenheim Securities is a member of SIPC (<u>http://www.sipc.org</u>). Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and our employees trading for our own account that reflect opinions that are contrary to the opinions expressed in this research. Guggenheim Securities or certain of its affiliates conducts an investment management business, trades for its own account, and conducts an investment business, and may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

We and our affiliates, officers, directors, and employees, excluding equity and credit analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research. We and our affiliates also may sell to or buy from customers on a principal basis the securities described herein. We and our affiliates also do business with, or that relates to, companies covered in Guggenheim Securities' research, and may have a position in the debt of the company or companies discussed herein.

This research is not an offer to sell or the solicitation of an offer to buy any security. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

TACTICAL TRADING IDEA DISCLAIMER

Guggenheim Securities, LLC produces "Tactical Trade Ideas" that identify short-term, catalyst-driven trading opportunities impacting companies within the Firm's coverage universe. Tactical Trade Ideas may exist on companies in this report and may be contrary to the analyst's published rating.

Copyright © 2014 by Guggenheim Securities, LLC, ("Guggenheim") a FINRA registered broker-dealer. All rights reserved. The contents of this report are based upon information or are obtained from sources that Guggenheim generally considers reliable, but Guggenheim makes no representations or warranties with respect to their accuracy, completeness, timeliness, suitability or otherwise, and assumes no responsibility to update them for subsequent events or knowledge. Guggenheim is not responsible for your use of this information.

GUGGENHEIM

Contact Information

NEW YORK SALES & TRADING DESK 212 292 4700

EQUITY TRADING DESK 212 292 4701

MEDIA INQUIRIES 310 367 6567

EMAIL general@guggenheimcm.com

Locations

NEW YORK 330 Madison Avenue New York, NY 10017

WASHINGTON, DC 1055 Thomas Jefferson Street, NW Suite 450 Washington, DC 20007

BOSTON 500 Boylston Street, 13th Floor Boston, MA 02116 LOS ANGELES 601 South Figueroa Street Suite 4005 Los Angeles, CA 90017

DALLAS 1717 McKinney Avenue Suite 870 Dallas, TX 75202

SAN FRANCISCO 50 California Street Suite 1515 San Francisco, CA 94111 NASHVILLE 104 Woodmont Blvd Suite 203 Nashville, TN 37205

RICHMOND 919 East Main Street Suite 1605 Richmond, VA 23219

Guggenheim Equity Research

ENERGY: EXPLORATION & PRODUCTION Rob Cordray, Analyst

robert.cordray@guggenheimpartners.com 972 638 5509

ENERGY: OIL SERVICES & EQUIPMENT Darren Gacicia, Analyst

darren.gacicia@guggenheimpartners.com 212 293 3054

Michael LaMotte, Analyst michael.lamotte@guggenheimpartners.com 972 638 5502

Wilson Waggoner, Associate wilson.waggoner@guggenheimpartners.com 972 638 5506

FINANCIAL SERVICES: BUSINESS DEVELOPMENT COMPANIES

Rahul Agarwal, Analyst rahul.agarwal@guggenheimpartners.com 615 208 1221

FINANCIAL SERVICES: REGIONAL & COMMUNITY BANKS, CARD NETWORKS

Taylor Brodarick, Analyst taylor.brodarick@guggenheimpartners.com 615 208 1222

David Darst, Analyst david.darst@guggenheimpartners.com 615 208 1224

FINANCIAL SERVICES: INSURANCE

Bijan Moazami, Analyst bijan.moazami@guggenheimpartners.com 202 747 9466

Marshall Coltrain, Associate marshall.coltrain@guggenheimpartners.com 202 747 9456

HEALTHCARE: BIOTECH

Bret Holley, Analyst bret.holley@guggenheimpartners.com 212 293 2820

HEALTHCARE: PHARMACEUTICALS Louise Chen, Analyst

louise.chen@guggenheimpartners.com 212 381 4195

Swati Kumar, Associate swati.kumar@guggenheimpartners.com 212 918 8754

Brandon Folkes, Associate brandon.folkes@guggenheimpartners.com 212 518 9976

RETAIL & CONSUMER

John Heinbockel, Analyst john.heinbockel@guggenheimpartners.com 212 381 4135

Steven Forbes, Associate steven.forbes@guggenheimpartners.com 212 381 4188

TMT: MEDIA & ENTERTAINMENT, CABLE & SATELLITE TV

Michael Morris, Analyst michael.morris@guggenheimpartners.com 804 253 8025

Curry Baker, Associate curry.baker@guggenheimpartners.com 804 253 8029